Botiacrine
 | |
| Clinical data | |
|---|---|
| Other names | Mo 876; DMA |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| ChEMBL | |
| CompTox Dashboard (EPA) | |
| Chemical and physical data | |
| Formula | C20H24N2OS |
| Molar mass | 340.49 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Botiacrine (INN; developmental code name Mo 876) is a drug of the tricyclic family described as an antiparkinsonian agent which was either never marketed or was possibly marketed outside of the United States.[1][2][3][4][5] It was first described in the literature by 1965.[1] The drug is an acridine derivative and is structurally related to the tricyclic antidepressant dimetacrine.[1]
References
- ^ a b c Elks J (2014). The Dictionary of Drugs: Chemical Data: Chemical Data, Structures and Bibliographies. Springer US. p. 170. ISBN 978-1-4757-2085-3. Retrieved 20 October 2024.
- ^ Negwer M (1994). Organic-chemical Drugs and Their Synonyms: (an International Survey). Akad.-Verlag. p. 1768. ISBN 978-3-05-500156-7. Retrieved 20 October 2024.
- ^ Unlisted Drugs. Unlisted Drugs Committee of the Pharmaceutical Section, Science-Technology Group, Special Libraries Association. 1977. pp. 112–113. Retrieved 20 October 2024.
- ^ "BOTIACRINE". Inxight Drugs. Retrieved 20 October 2024.
- ^ Publishing W (2013). Pharmaceutical Manufacturing Encyclopedia. Volumes 1-4. William Andrew. pp. 657–658. ISBN 978-0-8155-1856-3. Retrieved 20 October 2024.